Rosuvastatin + Atorvastatin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hypercholesteremia
Conditions
Hypercholesteremia
Trial Timeline
Jun 1, 2003 → Feb 1, 2005
NCT ID
NCT00239330About Rosuvastatin + Atorvastatin
Rosuvastatin + Atorvastatin is a phase 3 stage product being developed by AstraZeneca for Hypercholesteremia. The current trial status is completed. This product is registered under clinical trial identifier NCT00239330. Target conditions include Hypercholesteremia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00683618 | Phase 3 | Completed |
| NCT00620542 | Phase 3 | Completed |
| NCT00427960 | Approved | Terminated |
| NCT00395486 | Approved | Completed |
| NCT00296400 | Phase 2 | Completed |
| NCT00296387 | Phase 3 | Completed |
| NCT00329173 | Phase 3 | Completed |
| NCT00239330 | Phase 3 | Completed |
| NCT00653965 | Phase 3 | Completed |
| NCT00653588 | Phase 3 | Completed |
| NCT00654225 | Phase 3 | Completed |
| NCT00654485 | Phase 3 | Completed |
| NCT00653744 | Phase 3 | Completed |
Competing Products
5 competing products in Hypercholesteremia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atorvastatin, Lipitor | Astellas Pharma | Approved | 85 |
| Rosuvastatin + HMG CoA inhibitor | Shionogi | Approved | 85 |
| SHR-1209 + Placebo | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Rosuvastatin calcium | AstraZeneca | Phase 3 | 77 |
| MK-0524A + ER Niacin + Placebo | Merck | Phase 3 | 77 |